August 16, 2026

Retatrutide Q1 2027 BLA Plan, Cancer Peptide Vaccine +34% YoY Trials, Semaglutide Real-World Reality, PeptiDream Leadership

Lilly confirms retatrutide Q1 2027 BLA. Cancer peptide vaccine trials +34% YoY. Real-world semaglutide 5.9-12% vs 14.9% STEP-1. PeptiDream new EVPs.

4 stories · Covering clinical-trials, research, industry

Editor's Note

Sunday's peptide news synthesizes running pipeline and market-structure themes with limited fresh event flow. Eli Lilly (NYSE: LLY) confirmed on the July 2026 TRIUMPH-2 and TRIUMPH-3 readouts that the company plans to submit a Biologics License Application (BLA) for retatrutide (once-weekly injectable GLP-1/GIP/glucagon triple agonist peptide) to the FDA in Q1 2027, following TRIUMPH-2 documenting up to 20.8% weight loss and 1.6 percentage point HbA1c reduction in 1,152 adults with obesity and type 2 diabetes and TRIUMPH-3 confirming similar profiles across an additional patient population. Cancer peptide vaccine clinical trial registrations increased 34% year-over-year through 2026 with 78 tracked personalized-cancer-vaccine trials (70 Phase 1, 8 Phase 2), of which 56 are currently active; the majority target previously peptide-resistant solid tumors (pancreatic, colorectal, triple-negative breast cancer) with combination trials pairing checkpoint inhibitors with tumor-associated antigen or neoantigen peptide vaccines. Real-world evidence for Wegovy (semaglutide 2.4 mg) documented 5.9% to 12% mean body weight reduction at 6 to 12 months across registry and claims analyses, versus 14.9% in the STEP-1 registrational trial; the gap is adherence-driven, with missed doses, titration pauses, and stop-restart cycles flattening real-world curves relative to the tight-adherence STEP-1 population. And PeptiDream Inc., the Kawasaki-based peptide discovery platform, announced the appointment of three new Executive Vice Presidents, extending the leadership restructure that has accompanied the company's growing partnership deal book with Novartis, Merck, Genentech, AbbVie, and others.

Clinical Trials

Eli Lilly (NYSE: LLY) Plans to Submit a Biologics License Application (BLA) for Retatrutide (Once-Weekly Injectable GIP/GLP-1/Glucagon Triple Hormone Receptor Agonist Peptide) to the FDA in Q1 2027 Following the July 23, 2026 TRIUMPH-2 and TRIUMPH-3 Phase 3 Readouts, With TRIUMPH-2 in 1,152 Adults With Obesity and Type 2 Diabetes Documenting Up to 20.8% Mean Weight Loss and 1.6 Percentage Point HbA1c Reduction and TRIUMPH-3 Confirming Similar Efficacy Profiles Across an Additional Patient Population; TRIUMPH-1 (Obesity Without Diabetes) Delivered 28.7% Mean Weight Loss at 68 Weeks at the 12 mg Dose and TRIUMPH-4 (Obesity Plus Knee Osteoarthritis) Delivered 28.7% Weight Loss With 75.8% Reduction in WOMAC Pain Scores; Potential FDA Approval Expected in 2027-2028 With Retatrutide Positioned to Set the New Weight-Loss Ceiling in the Obesity Drug Class

Eli Lilly (NYSE: LLY) plans to submit a Biologics License Application (BLA) for retatrutide (once-weekly injectable GIP/GLP-1/glucagon triple hormone receptor agonist peptide) to the FDA in Q1 2027 following the July 23, 2026 TRIUMPH-2 and TRIUMPH-3 Phase 3 readouts. TRIUMPH-2 (obesity and type 2 diabetes) enrolled 1,152 adults and documented up to 20.8% mean weight loss and 1.6 percentage point HbA1c reduction at 68 weeks. TRIUMPH-3 confirmed similar efficacy profiles across an additional patient population. Combined with the earlier readouts (TRIUMPH-1 in obesity without diabetes at 28.7% mean weight loss at 68 weeks at the 12 mg dose, and TRIUMPH-4 in obesity plus knee osteoarthritis at 28.7% weight loss with 75.8% reduction in WOMAC pain scores), the retatrutide package now covers four major indication frames with consistent efficacy. Additional TRIUMPH readouts expected across 2026 in obstructive sleep apnea, chronic lower back pain, and cardio-renal-metabolic outcomes will strengthen the label breadth. Potential FDA approval is expected in 2027-2028, positioning retatrutide to set the new weight-loss ceiling in the obesity drug class at 28.7% (versus tirzepatide's 25.5% and semaglutide's 15% in the current approved landscape).

#eli-lilly #lly #retatrutide #triple-agonist #triumph-1 #triumph-2 #triumph-3 #triumph-4 #bla-q1-2027 #type-2-diabetes #20-8-percent-weight-loss #hba1c-reduction

Research

Cancer Peptide Vaccine Clinical Trial Registrations Increased 34% Year-Over-Year Through Mid-2026 With 78 Tracked Personalized Cancer Vaccine Trials (70 Phase 1, 8 Phase 2, of Which 56 Are Currently Active); Peptide Vaccines Represent the Most-Tested Modality at 31 Trials (Versus 15 Dendritic Cell Vaccines and 13 RNA Vaccines) and Target CD8+ or CD4+ T-Cell Responses Against Tumor-Associated Antigens (TAAs) or Tumor-Specific Antigens (TSAs); The Majority Target Solid Tumors Previously Considered Resistant to Peptide Therapies (Pancreatic, Colorectal, Triple-Negative Breast Cancer); Combination Trials Pairing Checkpoint Inhibitor Antibodies With Peptide Vaccine Regimens Are Enrolling Now, Converting Immunologically Cold Tumors to Hot Before Checkpoint Blockade

Cancer peptide vaccine clinical trial registrations increased 34% year-over-year through mid-2026 with 78 tracked personalized cancer vaccine trials (70 Phase 1, 8 Phase 2), of which 56 are currently active and 22 have been completed. Modality breakdown: peptide vaccines represent the most-tested category at 31 trials (39.7% of the field), followed by dendritic cell vaccines at 15 trials (19.2%) and RNA vaccines at 13 trials (16.7%). Peptide vaccines target CD8+ T-cell responses (cytotoxic T cells that directly kill tumor cells) or CD4+ T helper cell responses (immune coordination) against tumor-associated antigens (TAAs, proteins overexpressed in cancer versus normal tissue) or tumor-specific antigens (TSAs, mutation-derived neoantigens unique to individual patient tumors). Indication trend: the majority of newly-registered trials target solid tumors previously considered resistant to peptide therapies (pancreatic, colorectal, triple-negative breast cancer) rather than the historically peptide-friendly indications (melanoma, glioblastoma). Combination-therapy trend: paired regimens of checkpoint inhibitor antibodies (anti-PD-1, anti-PD-L1, anti-CTLA-4) with peptide vaccines are the fastest-growing category, based on the biology that peptide vaccines can convert immunologically cold tumors to hot (increased tumor-infiltrating lymphocytes) prior to checkpoint blockade, potentially expanding the checkpoint responder population.

#cancer-peptide-vaccine #personalized-cancer-vaccine #neoantigen #tumor-associated-antigen #tsa #taa #checkpoint-inhibitor-combination #pancreatic-cancer #colorectal-cancer #triple-negative-breast #cold-to-hot #34-percent-yoy

Research

Real-World Evidence for Wegovy (Semaglutide 2.4 mg Once Weekly Subcutaneous Injection) Documents 5.9% to 12% Mean Body Weight Reduction at 6 to 12 Months Across Registry and Claims Analyses, Compared to 14.9% Weight Loss in the STEP-1 Registrational Trial; The Gap Is Adherence-Driven With Missed Doses, Titration Pauses, and Stop-Restart Cycles Flattening Real-World Curves Relative to the Tight-Adherence STEP-1 Population; Cleveland Clinic Research Confirmed That Injectable Obesity Medications Produce Smaller Weight Loss in a Real-World Setting Compared to Randomized Clinical Trials; A Large Real-World Study of Nearly 8,000 Patients Found That Most People Who Discontinue GLP-1 Therapy Manage to Keep the Weight Off or Continue Losing by Restarting Treatment, Switching Medications, or Adopting Lifestyle Changes

Real-world evidence for Wegovy (semaglutide 2.4 mg once weekly subcutaneous injection) documents 5.9% to 12% mean body weight reduction at 6 to 12 months across registry and claims analyses. This compares to 14.9% weight loss in the STEP-1 registrational trial that supported the FDA approval. The gap is primarily adherence-driven: missed doses, titration pauses, insurance-driven dose changes, and stop-restart cycles flatten real-world curves relative to the tight-adherence STEP-1 population. Cleveland Clinic research confirmed that injectable obesity medications produce smaller weight loss in a real-world setting compared to randomized clinical trials, with the gap larger in patient subgroups facing financial barriers to consistent supply. A large real-world study of nearly 8,000 patients who discontinued GLP-1 therapy found that most manage to keep the weight off or continue losing by restarting treatment, switching medications (typically to tirzepatide or higher-dose Wegovy), or adopting lifestyle changes. Patient satisfaction is driven primarily by perceived effectiveness rather than tolerability: effective weight loss even with gastrointestinal side effects is associated with continued treatment adherence, while lower-efficacy responses lead to early discontinuation regardless of tolerability. The real-world evidence has implications for retatrutide's likely commercial trajectory: the 28.7% Phase 3 ceiling may translate to 15-20% in real-world use depending on adherence patterns, which is still substantially above semaglutide's real-world 5.9-12% range.

#semaglutide #wegovy #real-world-evidence #adherence #step-1 #cleveland-clinic #weight-regain #gi-side-effects #discontinuation #5-9-12-percent #retatrutide-real-world-implications

Industry

PeptiDream Inc. (TSE: 4587), the Kawasaki-Based Peptide Discovery Platform Company That Operates the Peptide Discovery Platform System (PDPS) for Constrained Cyclic Peptide Design and Runs an Extensive Partnership Book With Novartis, Merck, Genentech, AbbVie, Bristol Myers Squibb, and Eli Lilly Among Others, Announced the Appointment of Three New Executive Vice Presidents Extending the Leadership Restructure That Has Accompanied the Company's Multi-Year Deal-Book Growth and the Increasing Preclinical-to-Clinical Progression of Its Partnered Peptide Programs; PeptiDream's PDPS Platform Screens Trillion-Scale Diverse Non-Standard Peptide Libraries to Identify Molecules That Bind Target Proteins With High Affinity and Specificity, With Applications Spanning Oncology, Immunology, and Rare Disease Peptide Drug Development

PeptiDream Inc. (TSE: 4587), the Kawasaki-based peptide discovery platform company, announced the appointment of three new Executive Vice Presidents. The leadership restructure accompanies the company's multi-year deal-book growth and the increasing preclinical-to-clinical progression of its partnered peptide programs. Company background: PeptiDream operates the Peptide Discovery Platform System (PDPS), a proprietary technology for designing constrained cyclic peptides. PDPS uses genetic-code reprogramming to generate trillion-scale diverse libraries of non-standard peptides (containing modified amino acids not found in natural proteins), which are then screened to identify molecules that bind target proteins with high affinity and specificity. Applications span oncology (peptide-drug conjugates, radioligand-conjugated peptides), immunology (novel immune-modulating peptides), and rare disease peptide drug development. Partnership book: PeptiDream has active collaborations with Novartis (multiple targets), Merck (peptide-radioligand programs), Genentech/Roche (immuno-oncology), AbbVie (multiple targets), Bristol Myers Squibb, Eli Lilly (including the recent obesity-adjacent partnership), and multiple mid-cap biopharmaceutical companies. The constrained cyclic peptide modality PeptiDream specializes in sits between traditional linear peptides (subject to protease degradation and short half-lives) and small-molecule drugs (limited target diversity), and has grown as a distinct drug modality throughout the 2020s as GLP-1 and other peptide successes have expanded the industry's willingness to invest in peptide chemistry platforms.

#peptidream #peptide-discovery-platform #pdps #constrained-cyclic-peptide #novartis #merck #genentech #abbvie #eli-lilly #leadership-restructure #executive-vice-presidents #peptide-platform-technology